*Univ. Bordeaux, INSERM, BPH, U1219, Bordeaux, France;

†CHU de Bordeaux, Department of Ophthalmology, Bordeaux, France;

‡World Health Organization, Health Personnel Department, Geneva, Switzerland; and

§INSERM U 1296 “Radiation, Defense, Health, Environment”, Center Léon Bérard, Lyon, France.

Reprint requests: Audrey Cougnard-Gregoire, PhD, Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Team LEHA, UMR 1219, F-33000 Bordeaux, France; e-mail: [email protected]

Alienor study is funded by Laboratories Théa, Fondation Voir et Entendre, Agence Nationale de la Recherche (ANR 2010-PRSP-011 VISA), French Ministry of Health (PHRC 12_157, ECLAIR), and CFSR Recherche (Club Français des Specialistes de la Retine).

B. Amari, M. Boniol, J.-F. Doré, C. Helmer, and A. Cougnard-Gregoire: No financial/conflicting interests to disclose. B. Merle: received travel fees from Laboratoires Théa. J.-F. Korobelnik: consultant for AbbVie, Apellis, Bayer, Janssen, Nano Retina, Roche, Théa, and Carl Zeiss Meditec; Member of the DSMB for Alexion, Novo Nordisk. M.-N. Delyfer: consultant for AbbVie, Bayer, Horama, Horus Pharma, Novartis, Roche, and Théa. C. Delcourt: consultant for Allergan/AbbVie, Apellis, Chauvin-Bausch+Lomb, Laboratoires Théa, and Novartis.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.retinajournal.com).

Laboratories Théa participated in the design of the Alienor study, but none of the sponsors participated in the collection, management, statistical analysis, and interpretation of the data or in the preparation, review, or approval of the present manuscript.

C. Delcourt and A. Cougnard-Gregoire contributed equally as co-last authors.